健信生物 | 核心产品II/III期临床研究实现首例入组

健信生物医药

2025/10/20

查看原文

634

PD-1 仑伐替尼 TIM-3

2025年10月17日，健信生物科技（上海/宁波）有限公司（以下简称“健信生物”）自主研发的PD-1/TIM-3双特异性抗体LB1410联合仑伐替尼±LB4330针对免疫耐药宫颈癌的II/III期临床研究（登记号CTR20253433/NCT07177716）成功完成首例患者入组。该临床研究由肿瘤妇科知名专家吴小华教授担任Leading PI，将在全国范围内启动多家研究中心全面开展患者招募和入组工作。

这一里程碑事件标志着健信生物在攻克肿瘤免疫耐药领域迈出关键一步，也意味着公司迈上新台阶。

A Milestone: First Patient Dosed

in Phase II/III Trial for Core Asset

On October 17, 2025, L&L Bio (Shanghai/Ningbo) successfully enrolled the first patient in its Phase II/III clinical trial (Registration No.: CTR20253433/NCT07177716) investigating the PD-1/TIM-3 bispecific antibody LB1410, developed independently by the company, in combination with lenvatinib ± LB4330 for the treatment of immune-resistant cervical cancer.

The study is led by renowned gynecologic oncology expert Professor Wu Xiaohua as the Leading Principal Investigator (Leading PI) and will be conducted across multiple research centers nationwide to comprehensively initiate patient recruitment and enrollment.

This milestone event marks a critical step for L&L Bio in overcoming tumor immune resistance and signifies the company’s advancement to a new stage.

PD-1相关推荐